Clinical Trial

An Observational Study on the Assessment of Lung Cancer Using Liquid Biopsy for Collecting miRNA Expression Profile and DNA Methylation Biomarkers.

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 19, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to observe whether miRNA and DNA methylation collected through liquid biopsy can serve as a biomarker for evaluating lung cancer.
Trial Details
NCT Number NCT07182214
Lead Sponsor Pharus Taiwan, Inc.
Conditions Lung Cancer
Enrollment 1,340 participants
Start Date 2024-05-05
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-19